Coronary Stenting in Patients With Small Coronary Arteries at High Risk of Bleeding: Onyx ONE Clear

[1]  R. Virmani,et al.  Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. , 2020, International journal of cardiology.

[2]  M. Price,et al.  One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients , 2020, Circulation. Cardiovascular interventions.

[3]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[4]  M. Price,et al.  Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. , 2020, The New England journal of medicine.

[5]  G. Stone,et al.  Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. , 2019, The American journal of cardiology.

[6]  A. Zaman,et al.  Clinical outcomes in unselected patients treated with the PROMUS Element platinum‐chromium, everolimus‐eluting stent: Final five‐year results from the PE PROVE Study , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[8]  G. Mintz,et al.  The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss , 2018, Circulation. Cardiovascular interventions.

[9]  A. Yeung,et al.  Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions , 2017, Circulation. Cardiovascular interventions.

[10]  Shigeru Saito,et al.  First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. , 2017, JACC. Cardiovascular interventions.

[11]  M. Stoel,et al.  Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. , 2016, American heart journal.

[12]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[13]  P. Serruys,et al.  Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everol , 2011, JACC. Cardiovascular interventions.

[14]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[15]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[16]  J. López-Sendón,et al.  Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. , 2007, European heart journal.

[17]  G. Breithardt,et al.  Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents , 2005, Circulation.

[18]  Fernando Alfonso,et al.  Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. , 2004, Journal of the American College of Cardiology.